Gene therapy firm Orchard Therapeutics Ltd. is making plans for an MAA submission in Europe next year based on the full registrational dataset of its investigational gene therapy OTL-200 in metachromatic leukodystrophy (MLD).
OTL-200 was part of the gene therapy haul from GlaxoSmithKline PLC in 2018, which included Strimvelis for so-called bubble...








